This page contains affiliate links. We may earn a commission at no cost to you. How we earn
GLP-1Telemedicine
Your Telehealth Visit

Asynchronous vs. Live Video: Types of GLP-1 Telehealth Visits

Updated May 17, 2026

🔍 Key Takeaway

Most GLP-1 telehealth visits in 2026 are asynchronous (text/questionnaire-based), not live video. Async visits are faster and cheaper but offer less clinical depth. Live video is preferred for complex medical histories, dose changes with persistent side effects, and patients who want face-to-face interaction with their provider.

Two models, different trade-offs

When you sign up for a GLP-1 telehealth program, the "consultation" can mean very different things depending on the provider. Some conduct live video visits with a physician or NP. Others use an asynchronous model where you fill out a questionnaire and a provider reviews it without real-time interaction. Both are legal and used by legitimate providers — but they offer different levels of clinical engagement.

Asynchronous (text-based) visits

How it works: You complete a comprehensive health questionnaire online — medical history, current medications, allergies, weight history, contraindication screening. A licensed provider reviews your responses, determines eligibility, and either prescribes or requests additional information. Communication happens via messaging or portal, not real-time conversation.

Pros: Faster (often same-day review), no scheduling required, lower overhead so potentially lower cost, convenient for straightforward cases where the patient is otherwise healthy and just needs the prescription.

Cons: No real-time clinical dialogue, harder to ask nuanced questions, provider may miss context that would surface in conversation, less personalized titration guidance. Some research suggests that video visits produce more thorough evaluations, though real-world data on GLP-1 outcomes by visit type is limited.

Live video visits

How it works: You schedule a video call with a licensed provider who reviews your health information, asks questions in real time, and discusses treatment options face-to-face. The visit typically lasts 15–30 minutes for an initial consultation.

Pros: Real-time clinical interaction, ability to ask questions and get immediate answers, provider can observe you visually (some conditions are visually apparent), more thorough evaluation of complex medical histories, better for discussing side-effect management and titration decisions.

Cons: Requires scheduling, may take longer to get an appointment, potentially higher cost, may feel unnecessary for straightforward follow-up refills.

When each format makes sense

Async is fine for: Straightforward initial evaluations in otherwise healthy patients, routine refill requests where you're tolerating the medication well, and dose-stable follow-ups where nothing has changed.

Video is better for: Patients with complex medical histories (multiple medications, diabetes, cardiovascular disease), initial evaluations where the questionnaire raised flags, dose changes when side effects are persistent, and situations where you want to discuss switching medications or formats.

Many providers offer a hybrid model — async for intake and refills, with video available for clinical concerns. This is often the best of both worlds.

✅ Providers With Clinical Consultations

Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.

Found Health

From $99/mo program

$100 off first order

250K+ patients. 15+ medications including Wegovy ($499/mo) and Zepbound (from $349). Insurance navigation.

Get $100 Off
Paid link
Editor's Pick

Embody

$149 first month

$299/mo refills

Compounded semaglutide with metabolic report, 1:1 guidance, and personalized plan.

Start for $149
Paid link

Wellorithm

See current pricing

Comprehensive GLP-1 program with clinical oversight and personalized dosing.

Get Started
Paid link

Related Guides

What Happens During a GLP-1 Telehealth Visit →Red Flags in GLP-1 Telehealth Providers →

Sources

1. JAMA Network Open, "GLP-1 receptor agonist therapy via direct-to-consumer telemedicine." 2026.

2. ATA (American Telemedicine Association), Best Practice Guidelines. 2025.